Vericel Raises 2026 Revenue Guidance, Launches $200M Buyback After 22% Q2 Revenue Jump
VCEL sits 68% above its 52-week low of $28.95.
Summary
Vericel delivered a strong Q2 with revenue up 22% to $77.5M, driven by 23% MACI growth, and swung to a $2.2M net profit. The company raised full-year revenue guidance to $330-$340M, signaling confidence in sustained demand across both franchises. A newly authorized $200M share repurchase program, funded by $227M in cash and no debt, underscores management's conviction in the growth outlook. This follows a robust Q1 that saw a 30% revenue surge and a major BARDA contract. With MACI biopsies and implants hitting records and a UK marketing application submitted, the pipeline and commercial momentum are accelerating.
At the time of this announcement, VCEL was trading at $48.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $28.95 to $48.75. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.